Viral vectors used in production have the biggest limitations as starting materials for viral vector manufacturing, according to 55% cell and gene therapy professionals ina recent study byInforma Connect. Answers from the respondents, who were largely from biotech companies in North America and Europe, revealed the areas for improvement in the use of vectors across cell and gene therapy production.
Plasmids closely follow behind as the second most limiting raw material, selected by half of the respondents, in addition to cell lines (45%)，媒体(26%)和血清(25%).
在向病毒载体商业化生产过渡的情况下，61%的细胞和基因治疗专业人员认为供应量是最关键的痛点。下一条生产线在供应商资格认证之间的分配相当平均(39%), inefficiency in downstream processes (37%) and regulatory support (37%).
Overall quality monitoring was voted the greatest need for emerging tools in vector characterization. It was selected by a third of our respondents, whereas just under a quarter found downstream/purification to be the most urgent gap.
